Revvity, Inc. Common Stock (RVTY)

Revvity, Inc. (NYSERVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to serum and plasma.

Today, Revvity, Inc. (NYSERVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity’s rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software.

Revvity, Inc. (NYSERVTY), today announced it will present at the following investor conferences in March 2025:

Revvity, Inc. (NYSERVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024.

The Board of Directors of Revvity (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 9, 2025 to all shareholders of record at the close of business on April 18, 2025.

Revvity, Inc. (NYSERVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and strengthens Element’s momentum towards regulatory approval of the benchtop AVITI™ sequencing system.

Revvity, Inc. (NYSERVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc. (NYSERVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders.

Revvity, Inc. (NYSERVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA.

Revvity, Inc. (NYSERVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England’s renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fields.

Scale Biosciences (Scale BioTM), a leader in innovative and scalable single cell analysis solutions, and Revvity’s (NYSERVTY) BioLegend business, a leading provider of world-class biological reagents and tools, today announced the availability of a new, first-of-its-kind TotalSeqTM PhenocyteTM single-cell protein profiling solution that supports customers by more easily identifying and characterizing rare cell subtypes, which ultimately powers immunology and oncology research. The solution is enabled by the proprietary combination of Scale Biosciences’ Quantum Barcoding technology platform and BioLegend’s TotalSeqTM antibody conjugates.

Revvity, Inc. (NYSERVTY), will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL.

Revvity, Inc. (NYSERVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by members of Revvity’s senior management team on the Company’s key business initiatives, operational achievements and future financial outlook.

Revvity, Inc. (NYSERVTY), today reported financial results for the third quarter ended September 29, 2024.

The Board of Directors of Revvity, Inc. (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025.

Revvity, Inc. (NYSERVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert handwritten text on test request forms into a digitized format. This cutting-edge solution is now available to clinical laboratories, aiming to streamline workflows and reduce manual data entry tasks.

Revvity, Inc. (NYSERVTY) today unveils its annual Impact Report, a declaration of the Company’s sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity’s continued evolution and strengthened commitments to creating a lasting, positive impact on the world.

Revvity, Inc. (NYSERVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc. (NYSERVTY), announced today the launch of the in-vitro diagnostic EURORealTimeTM APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’s disease.

Revvity, Inc. (NYSERVTY), today announced it will present at the following investor conferences in September 2024:

Revvity, Inc. (NYSERVTY), today reported financial results for the second quarter ended June 30, 2024.

The Board of Directors of Revvity (NYSERVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024.

Revvity, Inc. (NYSERVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Revvity, Inc. (NYSERVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL.

Revvity, Inc. (NYSERVTY), today reported financial results for the first quarter ended March 31, 2024.